NEW YORK (GenomeWeb) – Natera and BGI Genomics said today that they have signed a $50 million partnership to commercialize Natera's circulating tumor DNA Signatera minimal residual disease (MRD) test in China and to develop reproductive health tests in "select markets," all using BGI's sequencing technology and instruments.